cloudfront

Report Detail

Pharma & HealthcareGlobal Renin-Inhibitors Market Insights, Forecast to 2025

  • RnM3115736
  • |
  • 15 March, 2019
  • |
  • Global
  • |
  • 111 pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global Renin-Inhibitors Market Insights, Forecast to 2025

Table of Contents

    1 Study Coverage

    • 1.1 Renin-Inhibitors Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Renin-Inhibitors Market Size Growth Rate by Product
      • 1.4.2 150mg/Tablet
      • 1.4.3 300mg/Tablet
    • 1.5 Market by End User
      • 1.5.1 Global Renin-Inhibitors Market Size Growth Rate by End User
      • 1.5.2 Age below 45
      • 1.5.3 Age 45-55
      • 1.5.4 Age 55-65
      • 1.5.5 Age above 65
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Renin-Inhibitors Market Size
      • 2.1.1 Global Renin-Inhibitors Revenue 2014-2025
      • 2.1.2 Global Renin-Inhibitors Sales 2014-2025
    • 2.2 Renin-Inhibitors Growth Rate by Regions
      • 2.2.1 Global Renin-Inhibitors Sales by Regions
      • 2.2.2 Global Renin-Inhibitors Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Renin-Inhibitors Sales by Manufacturers
      • 3.1.1 Renin-Inhibitors Sales by Manufacturers
      • 3.1.2 Renin-Inhibitors Sales Market Share by Manufacturers
      • 3.1.3 Global Renin-Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Renin-Inhibitors Revenue by Manufacturers
      • 3.2.1 Renin-Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Renin-Inhibitors Revenue Share by Manufacturers (2014-2019)
    • 3.3 Renin-Inhibitors Price by Manufacturers
    • 3.4 Renin-Inhibitors Manufacturing Base Distribution, Product Types
      • 3.4.1 Renin-Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Renin-Inhibitors Product Type
      • 3.4.3 Date of International Manufacturers Enter into Renin-Inhibitors Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Renin-Inhibitors Sales by Product
    • 4.2 Global Renin-Inhibitors Revenue by Product
    • 4.3 Renin-Inhibitors Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Renin-Inhibitors Breakdown Data by End User

    6 North America

    • 6.1 North America Renin-Inhibitors by Countries
      • 6.1.1 North America Renin-Inhibitors Sales by Countries
      • 6.1.2 North America Renin-Inhibitors Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Renin-Inhibitors by Product
    • 6.3 North America Renin-Inhibitors by End User

    7 Europe

    • 7.1 Europe Renin-Inhibitors by Countries
      • 7.1.1 Europe Renin-Inhibitors Sales by Countries
      • 7.1.2 Europe Renin-Inhibitors Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Renin-Inhibitors by Product
    • 7.3 Europe Renin-Inhibitors by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Renin-Inhibitors by Countries
      • 8.1.1 Asia Pacific Renin-Inhibitors Sales by Countries
      • 8.1.2 Asia Pacific Renin-Inhibitors Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Renin-Inhibitors by Product
    • 8.3 Asia Pacific Renin-Inhibitors by End User

    9 Central & South America

    • 9.1 Central & South America Renin-Inhibitors by Countries
      • 9.1.1 Central & South America Renin-Inhibitors Sales by Countries
      • 9.1.2 Central & South America Renin-Inhibitors Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Renin-Inhibitors by Product
    • 9.3 Central & South America Renin-Inhibitors by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Renin-Inhibitors by Countries
      • 10.1.1 Middle East and Africa Renin-Inhibitors Sales by Countries
      • 10.1.2 Middle East and Africa Renin-Inhibitors Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Renin-Inhibitors by Product
    • 10.3 Middle East and Africa Renin-Inhibitors by End User

    11 Company Profiles

    • 11.1 Novartis
      • 11.1.1 Novartis Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Novartis Renin-Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Novartis Renin-Inhibitors Products Offered
      • 11.1.5 Novartis Recent Development
    • 11.2 Noden Pharma
      • 11.2.1 Noden Pharma Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Noden Pharma Renin-Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Noden Pharma Renin-Inhibitors Products Offered
      • 11.2.5 Noden Pharma Recent Development

    12 Future Forecast

    • 12.1 Renin-Inhibitors Market Forecast by Regions
      • 12.1.1 Global Renin-Inhibitors Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Renin-Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.2 Renin-Inhibitors Market Forecast by Product
      • 12.2.1 Global Renin-Inhibitors Sales Forecast by Product 2019-2025
      • 12.2.2 Global Renin-Inhibitors Revenue Forecast by Product 2019-2025
    • 12.3 Renin-Inhibitors Market Forecast by End User
    • 12.4 North America Renin-Inhibitors Forecast
    • 12.5 Europe Renin-Inhibitors Forecast
    • 12.6 Asia Pacific Renin-Inhibitors Forecast
    • 12.7 Central & South America Renin-Inhibitors Forecast
    • 12.8 Middle East and Africa Renin-Inhibitors Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Renin-Inhibitors Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
      USA is still the largest consumption region of Tekturna, occupied about 56% market share globally, with revenue 39.21 million USD in 2017. At the same time, Asia will see the considerable growth since Noden Pharma DAC had successfully entered into an agreement with Orphan Pacific (Japan) and Lee’s Pharmaceutical Holdings Limited (China).
      The global Renin-Inhibitors market is valued at 69 million US$ in 2018 and will reach 120 million US$ by the end of 2025, growing at a CAGR of 6.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Renin-Inhibitors market based on company, product type, end user and key regions.

      This report studies the global market size of Renin-Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Renin-Inhibitors in these regions.
      This research report categorizes the global Renin-Inhibitors market by top players/brands, region, type and end user. This report also studies the global Renin-Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Novartis
      Noden Pharma

      Market size by Product
      150mg/Tablet
      300mg/Tablet
      Market size by End User
      Age below 45
      Age 45-55
      Age 55-65
      Age above 65

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Renin-Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Renin-Inhibitors market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Renin-Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Renin-Inhibitors submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Renin-Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Tablet). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Renin-Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.




      Summary:
      Get latest Market Research Reports on Renin-Inhibitors . Industry analysis & Market Report on Renin-Inhibitors is a syndicated market report, published as Global Renin-Inhibitors Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Renin-Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      2,618.85
      3,928.28
      5,237.70
      3,588.78
      5,383.17
      7,177.56
      472,446.00
      708,669.00
      944,892.00
      258,622.26
      387,933.39
      517,244.52
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report